9HA Stock Overview
A clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Elicio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.50 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$3.00 |
| Beta | 0 |
| 11 Month Change | 9.76% |
| 3 Month Change | 25.70% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9HA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.3% | -1.1% | 1.1% |
| 1Y | n/a | -18.8% | 7.2% |
Return vs Industry: Insufficient data to determine how 9HA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 9HA performed against the German Market.
Price Volatility
| 9HA volatility | |
|---|---|
| 9HA Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9HA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9HA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 32 | Bob Connelly | elicio.com |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations.
Elicio Therapeutics, Inc. Fundamentals Summary
| 9HA fundamental statistics | |
|---|---|
| Market cap | €49.78m |
| Earnings (TTM) | -€44.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 9HA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9HA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$46.84m |
| Earnings | -US$46.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -104.5% |
How did 9HA perform over the long term?
See historical performance and comparison